Kanamycin-Pos

Kanamycin, the active ingredient in Kanamycin-Pos, is an aminoglycoside antibiotic presented as a sterile ophthalmic preparation for ocular use. It treats bacterial conjunctivitis, keratitis and other ocular bacterial infections in patients requiring topical therapy.

GNH USA supplies Kanamycin-Pos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanamycin-Pos is an aminoglycoside antibiotic indicated for bacterial infections of the eye and related structures.

- Bacterial conjunctivitis: reduces bacterial load and promotes resolution of infection. - Keratitis: eradicates pathogenic bacteria to aid corneal healing. - Other ocular bacterial infections: provides broad‑spectrum coverage for susceptible organisms.

Kanamycin‑Pos may cause local and systemic adverse reactions, although many patients tolerate it well.

Common Side Effects: - Eye irritation or burning sensation. - Redness of the conjunctiva. - Excessive tearing or discharge. - Transient blurred vision. - Mild allergic conjunctivitis.

Serious or Rare Side Effects: - Systemic ototoxicity with prolonged absorption. - Nephrotoxicity in patients with compromised renal function. - Severe allergic reaction, including anaphylaxis. - Corneal ulceration or perforation. - Permanent vision loss in rare cases.

Before using Kanamycin‑Pos, consider the following safety measures.

- Assess renal function: adjust use if renal impairment is present. - Monitor for ototoxicity: discontinue if hearing changes occur. - Avoid in patients with known hypersensitivity to aminoglycosides. - Use only for confirmed or strongly suspected bacterial eye infections. - Do not combine with other ototoxic ophthalmic agents without supervision. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Kanamycin‑Pos can interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Systemic aminoglycosides: increase risk of cumulative ototoxicity and nephrotoxicity. - Loop diuretics: potentiate renal toxicity. - Neuromuscular blocking agents: may enhance neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Topical ophthalmic anesthetics: raise risk of corneal toxicity. - Corticosteroid eye drops: may mask infection signs. - NSAID eye drops: could add to ocular irritation.